A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Status:
Recruiting
Trial end date:
2023-06-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to: (a) characterize the safety and tolerability of and to
identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with
cetrelimab, and for erdafitinib in combination with cetrelimab and platinum (cisplatin and
carboplatin) chemotherapy and; (b) to evaluate the safety and clinical activity of
erdafitinib alone and in combination with cetrelimab in cisplatin-ineligible participants
with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth
factor receptor (FGFR) gene alterations and no prior systemic therapy for metastatic disease.